Last reviewed · How we verify
NCT01313533
Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes
Phase 1/Phase 2 trial testing Polyarginine in Atherosclerosis in 540 participants. Status unknown.
1 December 2019
Quick facts
| Lead sponsor | St. Luke's Hospital, Chesterfield, Missouri |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | factorial |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 540 |
| Start date | 1 March 2015 |
| Primary completion | 1 December 2019 |
| Estimated completion | 1 November 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Polyarginine — full drug profile →
- Vein soak treated with Lactated Ringers Solution — full drug profile →
Conditions studied
- Atherosclerosis — all drugs for Atherosclerosis →
Sponsor
St. Luke's Hospital, Chesterfield, Missouri
Who can join
Adults 25 to 95, any sex, with Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
To study the effects of arginine on saphenous vein graft patency rates
Time frame: 12 months post operation
To study the effects of arginine on saphenous vein graft patency rates
Sponsor's own description
The purpose of this study is to study the effects of polyarginine treated vein grafts on graft patency for patients undergoing coronary artery bypass surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT01313533
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atherosclerosis
Currently open trials in the same condition.
- NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT06788431 — A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary · EARLY_PHASE1 · recruiting
- NCT06676046 — Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions · recruiting
- NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting
Other St. Luke's Hospital, Chesterfield, Missouri trials
Trials by the same sponsor.
- NCT02232958 — Effect of HBO on Functional Connectivity of Resting State Networks in Patients With Cerebral Small Vessel Disease · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01313533 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St. Luke's Hospital, Chesterfield, Missouri
- Last refreshed: 2 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01313533.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing